U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H27N3O3
Molecular Weight 369.4574
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICAINOPROL

SMILES

CC(C)NCC(O)COC1=CC=CC2=C1N(CCC2)C(=O)C3=CC=CN=C3

InChI

InChIKey=AUIHHZBJBKRDIE-UHFFFAOYSA-N
InChI=1S/C21H27N3O3/c1-15(2)23-13-18(25)14-27-19-9-3-6-16-8-5-11-24(20(16)19)21(26)17-7-4-10-22-12-17/h3-4,6-7,9-10,12,15,18,23,25H,5,8,11,13-14H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C21H27N3O3
Molecular Weight 369.4574
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Nicainoprol, also known as RU-42924, is calcium channel antagonist and a putative class I antiarrhythmic agent. Nicainoprol was shown to be useful in the prevention and treatment of arrhythmias associated with acute myocardial infarction. Nicainoprol had been in phase II clinical trials for the treatment of arrhythmia. However, this research has been discontinued.

CNS Activity

Curator's Comment: Nicainoprol induced some central nervous system effect including vomiting in conscious coronary ligated dogs.

Originator

Curator's Comment: The compound was originally developed by Roussel-Uclaf, Hoechst Marion Roussel and Cassella-Riedel. Roussel-Uclaf later became part of Hoechst Marion Roussel, which merged with Rhône-Poulenc Rorer to form Aventis Pharma. Aventis has since merged with Sanofi-Synthelabo to form Sanofi-Aventis.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1672 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NICAINOPROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2450 ng/mL
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NICAINOPROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10205 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NICAINOPROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7388 ng × h/mL
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NICAINOPROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
104.2 min
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NICAINOPROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
106.6 min
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NICAINOPROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of nicainoprol on reperfusion arrhythmia in the isolated working rat heart and on ischemia and reperfusion arrhythmia and myocardial infarct size in the anesthetized rat.
1987 Nov 17
Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril.
1989 Dec
Electrophysiologic effects of nicainoprol, a putative class I antiarrhythmic agent, on the guinea pig ventricular papillary muscle.
1989 May
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Nicainoprol was also used IV in patients with paroxysmal supraventricular tachycardias: Nicainoprol was administered intravenously as a bolus followed by continuous infusion of 1.5 mg/kg in two and of 2 mg/kg in 27 patients over one hour. Nicainoprol was given as a bolus of 1.5-2 mg/kg during sinus rhythm in 11 patients or during induced supraventricular tachycardia in 18.
Ventricular arrhythmia: doses of 200, 400, 600 mg three times daily in randomized order
Route of Administration: Oral
In Vitro Use Guide
The effects of nicainoprol (1-50 uM) on the transmembrane action potentials in isolated papillary muscles of the guinea pig was examined. Nicainoprol (greater than or equal to 5 uM) produced dose-dependent decreases in the maximal upstroke velocity (Vmax) of the action potential. Only the highest concentration (50 uM) decreased the amplitude and the overshoot of the action potential and shortened its duration at 50 or 90% repolarization levels (APD50, APD90). The potential at rest was not affected by any concentration tested (1-50 uM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:04:15 GMT 2023
Edited
by admin
on Sat Dec 16 16:04:15 GMT 2023
Record UNII
1UA960P80H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NICAINOPROL
INN  
INN  
Official Name English
METHANONE, (3,4-DIHYDRO-8-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-1(2H)-QUINOLINYL)-3-PYRIDINYL-
Systematic Name English
QUINOLINE, 1,2,3,4-TETRAHYDRO-8-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-1-(3-PYRIDINYLCARBONYL)-
Systematic Name English
nicainoprol [INN]
Common Name English
(±)-1,2,3,4-TETRAHYDRO-8-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)-1-NICOTINOYLQUINOLINE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C29576
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
Code System Code Type Description
INN
5063
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
FDA UNII
1UA960P80H
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
PUBCHEM
71147
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
CAS
76252-06-7
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
ECHA (EC/EINECS)
278-403-8
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
SMS_ID
100000084165
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
NCI_THESAURUS
C76553
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
MESH
C047768
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
ChEMBL
CHEMBL2106788
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
EPA CompTox
DTXSID10868395
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
EVMPD
SUB09221MIG
Created by admin on Sat Dec 16 16:04:15 GMT 2023 , Edited by admin on Sat Dec 16 16:04:15 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY